| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
Enrofloxacin (BAY-Vp2674; PD160788; trade name Baytril) is a potent fluoroquinolone antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis. Enrofloxacin is developed by the Bayer group. Enrofloxacin is currently approved by the FDA for the treatment of individual pets and domestic animals in the United States. Enrofloxacin is a broad-spectrum bactericidal antibiotic. Although the mechanism of action is not wellunderstood, Enrofloxacin is effective against a broad spectrum of gram-positive and gram-negativebacteria including most species of the following: Pseudomonas aeruginosa, Klebsiella, E.coli., Enterobacter, Campylobacter, Shigella, Salmonella, Aeromonas, Haemophilus, Proteus, Yersinia, Serratia, Vibrio, Brucella, Chlamydia, Staphylococci (including some methicillin resistant strains).
| Targets |
Quinolone
|
|---|---|
| ln Vitro |
Cattle suffering from pneumonia, mastitis, arthritis, and other symptoms can be caused by the global pathogen Mycoplasma bovis. Within the tested group of fluoroquinolones, the Hungarian strains' profiles of antibiotic susceptibility are consistent. Enrofloxacin inhibits three isolates (MYC44, MYC45, and MYC46) with MIC values ≥10 μg/mL, while the remaining strains have MICs ≤0.312 or 0.625 μg/mL[1].
|
| ln Vivo |
Eighty mice are subjected to a sixty-minute period of transient middle cerebral artery occlusion (MCAo), followed by reperfusion. Following MCAo, animals are randomized to receive a therapeutic medication (n=25; Enrofloxacin) upon diagnosis of lung infection, or a daily preventive medication (n=26; Enrofloxacin) beginning on the day of MCAo. Following the onset of clinical signs (general health score greater than 6), which typically occur between days 4 and 6, standard treatment was initiated right away. When compared to placebo treatment, both preventive and conventional antibiotic treatments utilizing enrofloxacin increase survival in a comparable manner[2].
|
| Animal Protocol |
Mice [2]
Male C57Bl6/J mice aged 11–14 weeks are utilized. Over the course of seven days, animals treated with antibiotics receive a daily oral dose of 10 mg/kg body weight administered via feeding needle every 12 hours. Enrofloxacin (2.5% oral solution) is dispensed in saline (2 mg/mL). In contrast, animals receiving a placebo receive the same amount of saline via feeding needle. After emerging from reperfusion anesthesia, the animals in the preventive antibiotic group were given Enrofloxacin (about an hour after the procedure). Therapeutic antibiotic treatment is started as soon as clinical symptoms (general health score >5) appear and an MRI confirms the lung infection (signal rate ≥5%). Allocation to groups is done at random[2]. |
| References |
|
| Molecular Formula |
C19H22FN3O3
|
|---|---|
| Molecular Weight |
359.3947
|
| Exact Mass |
359.16
|
| Elemental Analysis |
C, 63.50; H, 6.17; F, 5.29; N, 11.69; O, 13.36
|
| CAS # |
93106-60-6
|
| Related CAS # |
Enrofloxacin monohydrochloride;93106-59-3;Enrofloxacin-d5;1173021-92-5
|
| Appearance |
Solid powder
|
| SMILES |
C1CC1n1c2cc(c(cc2c(=O)c(c1)C(=O)O)F)N1CCN(CC1)CC
|
| InChi Key |
SPFYMRJSYKOXGV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
|
| Chemical Name |
3-Quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-4-oxo-, hydrochloride
|
| Synonyms |
Baytril; Enrofloxacine; CFPQ; Bay-Vp-2674; BAY-Vp2674; PD 160788; BAY-Vp2674; PD160788; BAY-Vp 2674; PD-160788; endrofloxicin.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
4-Methylpyridine : ~30 mg/mL
H2O : ~1 mg/mL (~2.78 mM) DMSO : 1~10 mg/mL ( 2.78~27.82 mM ) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (2.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 1 mg/mL (2.78 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7825 mL | 13.9125 mL | 27.8249 mL | |
| 5 mM | 0.5565 mL | 2.7825 mL | 5.5650 mL | |
| 10 mM | 0.2782 mL | 1.3912 mL | 2.7825 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
